[go: up one dir, main page]

UY36675A - Compuestos cíclicos que tienen una acción inhibidora de la señalización del receptor de tipo toll 4 (tlr4) - Google Patents

Compuestos cíclicos que tienen una acción inhibidora de la señalización del receptor de tipo toll 4 (tlr4)

Info

Publication number
UY36675A
UY36675A UY0001036675A UY36675A UY36675A UY 36675 A UY36675 A UY 36675A UY 0001036675 A UY0001036675 A UY 0001036675A UY 36675 A UY36675 A UY 36675A UY 36675 A UY36675 A UY 36675A
Authority
UY
Uruguay
Prior art keywords
tlr4
toll
signaling
cyclic compounds
inhibiting action
Prior art date
Application number
UY0001036675A
Other languages
English (en)
Inventor
Negoro Nobuyuki
Kobayashi Toshitake
Saitoh Morihisa
Wada Yasufumi
Nara Hiroshi
Yamasaki Masashi
Tanaka Takahiro
Kitamoto Naomi
Katoh Taisuke
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of UY36675A publication Critical patent/UY36675A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/12—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona compuestos que tienen una acción inhibidora de la señalización del receptor de tipo Toll 4 (TLR4, por su sigla en inglés) útiles como fármacos preventivos y terapéuticos de una enfermedad inflamatoria y/o una enfermedad del sistema nervioso central o enfermedades tales como neuropatía periférica inducida por quimioterapia (CIPN), dolor neuropático inducido por quimioterapia (CINP), lesión hepática, lesión por isquemia-reperfusión (IRI) y similares. La presente invención se refiere a un compuesto representado por la fórmula (I) y una sal del mismo en la que, cada símbolo se explica con mayor detalle en la memoria descriptiva
UY0001036675A 2015-05-08 2016-05-06 Compuestos cíclicos que tienen una acción inhibidora de la señalización del receptor de tipo toll 4 (tlr4) UY36675A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015095817 2015-05-08

Publications (1)

Publication Number Publication Date
UY36675A true UY36675A (es) 2016-12-30

Family

ID=56132991

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036675A UY36675A (es) 2015-05-08 2016-05-06 Compuestos cíclicos que tienen una acción inhibidora de la señalización del receptor de tipo toll 4 (tlr4)

Country Status (11)

Country Link
US (3) US9611244B2 (es)
EP (1) EP3294706B1 (es)
JP (1) JP6718884B2 (es)
CN (1) CN107835800B (es)
AR (1) AR104539A1 (es)
CA (1) CA2985325C (es)
EA (1) EA033083B1 (es)
ES (1) ES2772703T3 (es)
TW (1) TW201704206A (es)
UY (1) UY36675A (es)
WO (1) WO2016182036A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611244B2 (en) * 2015-05-08 2017-04-04 Takeda Pharmaceutical Company Limited Cyclic compounds
EP3511320A4 (en) 2016-09-09 2020-04-15 Takeda Pharmaceutical Company Limited CYCLIC CONNECTION
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2214398C2 (ru) * 1998-03-09 2003-10-20 Такеда Кемикал Индастриз, Лтд. Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения
CN1210257C (zh) 1999-08-06 2005-07-13 武田药品工业株式会社 取代的芳香环化合物及其制备方法和用途
JP2004002370A (ja) * 2002-04-08 2004-01-08 Takeda Chem Ind Ltd 重症セプシス予防治療剤
US20060058288A1 (en) 2002-04-08 2006-03-16 Masayuki Ii Severe sepsis preventive therapeutic agent
AU2006289921B2 (en) 2005-09-14 2010-11-18 Daiichi Sankyo Company, Limited Substituted cycloalkene derivative
JP2008260760A (ja) 2007-03-12 2008-10-30 Daiichi Sankyo Co Ltd 置換シクロアルケン誘導体を含有する医薬組成物
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
NZ601635A (en) 2010-01-27 2013-06-28 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
US9611244B2 (en) * 2015-05-08 2017-04-04 Takeda Pharmaceutical Company Limited Cyclic compounds

Also Published As

Publication number Publication date
ES2772703T3 (es) 2020-07-08
CN107835800A (zh) 2018-03-23
JP6718884B2 (ja) 2020-07-08
US20160326102A1 (en) 2016-11-10
CA2985325C (en) 2023-09-26
US9828357B2 (en) 2017-11-28
CA2985325A1 (en) 2016-11-17
US20170066737A1 (en) 2017-03-09
JP2018516875A (ja) 2018-06-28
US9611244B2 (en) 2017-04-04
EA033083B1 (ru) 2019-08-30
EP3294706A1 (en) 2018-03-21
WO2016182036A1 (en) 2016-11-17
CN107835800B (zh) 2019-11-26
US9533966B2 (en) 2017-01-03
US20160326133A1 (en) 2016-11-10
EA201792469A1 (ru) 2018-06-29
TW201704206A (zh) 2017-02-01
BR112017023818A2 (pt) 2018-07-31
EP3294706B1 (en) 2019-12-04
AR104539A1 (es) 2017-07-26

Similar Documents

Publication Publication Date Title
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
CO2020015176A2 (es) Compuestos novedosos
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
CL2020000747A1 (es) Formulaciones de niraparib.
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
UY36675A (es) Compuestos cíclicos que tienen una acción inhibidora de la señalización del receptor de tipo toll 4 (tlr4)
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX388592B (es) Compuestos y metodos terapeuticos.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
EA201691160A1 (ru) Антагонисты s1p3
BR112017024304A2 (pt) processo para a preparação de um extrato de cérebro animal
BR112019000946A2 (pt) compostos para imagiologia dos agregados da proteína tau
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
EA201990399A1 (ru) Соединения, композиции и их применение
CL2017002229A1 (es) Inhibidores de bace1.
BR112017020180A2 (pt) derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221114